Several different major newspapers published the article originally published in the NY Times Health Section on the same day, June 9 th, 2015. This is typical of Big Pharma’s press release actions to the media, and the media obligingly complies. Big Pharma pays for lots of media advertising.

Here are a couple of excerpts from the article hyping new cholesterol drugs that appeared on the NY Times, “Federal Panel Backs Approval of New Drug to Fight Heart Attacks” and was echoed simultaneously in several large newspapers throughout the country.

“An expert group recommended on Tuesday that the Food and Drug Administration approve a powerful new drug to protect against heart attacks. If approved, it would be the first in a major new class of medicines in a generation that significantly lower levels of cholesterol, the leading cause of heart disease.”

“The panel, in a 13 to 3 vote, recommended the approval of Sanofi and Regeneron Pharmaceuticals’ drug, alirocumab [brand name Praulent]. On Wednesday, the committee will turn to Amgen’s drug, evolocumab [brand name Repatha]. The F.D.A. usually follows the recommendations of its advisory panels, but not always.”

Here’s an impressive comment in this press release promotional article, Dr. Joshua W. Knowles, a Stanford cardiologist, called the medicines “a triumph of the modern genetic revolution.”

But It’s All Marketing Hype, Not Science Based Reporting

And just who comprise these “expert groups” in Federal “advisory panels”? They are representatives from the pharmaceutical companies, of course.

“Good fellas” drug reps in advisory panel

Here’s how Shane Ellison, former Big Pharma now independent biochemist, blogger, and author of Over the Counter Natural Cures, Expanded Edition: Take Charge of Your Health in 30 Days with 10 Lifesaving Supplements for under $10 bluntly explained these advisory panels.

“A group of shareholders masquerading as an FDA advisory panel approves of you swallowing their brand new, toxic, cholesterol lowering drug.”

NOT A SINGLE SCIENTIFIC STUDY has ever proven that “low cholesterol
prevents heart disease.”

LOW CHOLESTEROL DESTROYS THE BODY.

HAVING LOW CHOLESTEROL is a great way to wipe away your hormones and your myelin sheath [the protective lipid coating on the central nervous system], causing cancer and Alzheimer’s [and eliminating the first phase of converting sunshine to vitamin D].

THE TRUE CAUSE OF HEART DISEASE has nothing to do with high cholesterol [some cardiologists claim cholesterol rushes to patch up arterial damage from inflammation in arteries, which are the real issues that cause hear disease].

Another excerpt from the NY Times article explains: “The agency [FDA] says that if it approves the drugs based on their effects on cholesterol, the approval will not be rescinded even if trials now underway fail to show the drugs reduce the risk of heart attacks and deaths.”

That seems a tacit implication that the drug’s approval will not be rescinded even as terrible side effects and deaths ravage many who attempt to lower cholesterol with these drugs, such as the statin drug Lipitor.

The new drugs are injected biweekly. So far, after almost two years of phase three human testing with alirocumab, the actual improvement for improved heart health is miniscule. What has been impressive is the increased amount of cholesterol reduction based on subjects who are on statins dosed to maximum without noticeable serious side effects.

So it appears that both new cholesterol reducing drugs may be added to statins, which already demonstrated side effects that can be disastrous. But is cholesterol reduction really the answer to improving heart health? More and more experts don’t think so anymore. As long as the myth remains, Big Pharma is looking at some big money with these new drugs.

The injected treatments are expensive. Insurance companies may be reluctant to cover them. The only way to bring the expense down is to do what has been done with statins – prescribe them for patients who who haven’t had any heart attacks. And that’s what has created huge revenues for statins while creating serious side effects.

The cholesterol treadmill continues for no real reason but Big Pharma profits.

Paul Fassais a contributing staff writer for REALfarmacy.com. His pet peeves are the Medical Mafia’s control over health and the food industry and government regulatory agencies’ corruption. Paul’s valiant contributions to the health movement and global paradigm shift are world renowned. Visit his blog by following this link and follow him on Twitter here.